在卡泊芬净治疗期间，光滑球拟酵母菌产生棘白菌素类耐药性。
Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.
机构信息
Institut Pasteur, National Reference Center for Mycoses and Antifungals, Molecular Mycology Unit, Paris, France.
出版信息
J Clin Microbiol. 2011 Jun;49(6):2304-6. doi: 10.1128/JCM.00325-11. Epub 2011 Apr 13.
Abstract
Clavispora lusitaniae is an opportunistic human pathogen responsible for 0.6 to 2% of candidemia. This species is intrinsically susceptible to echinocandins. Nevertheless, in this study, development of echinocandin resistance in C. lusitaniae isolates was observed during caspofungin treatment. This resistance resulted from missense mutation in the echinocandin target Fks1 gene.
摘要
卢特西亚拟内孢霉是一种机会性人类病原体，占念珠菌血症的 0.6%至 2%。该物种对棘白菌素类药物固有敏感。然而，在这项研究中，在卡泊芬净治疗期间观察到卢特西亚拟内孢霉分离株对棘白菌素类药物的耐药性发展。这种耐药性是由于棘白菌素类药物靶标 Fks1 基因的错义突变引起的。
相似文献
1
Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.在卡泊芬净治疗期间，光滑球拟酵母菌产生棘白菌素类耐药性。
J Clin Microbiol. 2011 Jun;49(6):2304-6. doi: 10.1128/JCM.00325-11. Epub 2011 Apr 13.
2
Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans.焦磷酸测序法检测白色念珠菌中FKS1基因的突变，这些突变会导致对棘白菌素的敏感性降低。
Antimicrob Agents Chemother. 2008 Nov;52(11):4145-8. doi: 10.1128/AAC.00959-08. Epub 2008 Sep 15.
3
Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.全球分析光滑念珠菌棘白菌素耐药性的进化和机制。
PLoS Pathog. 2012;8(5):e1002718. doi: 10.1371/journal.ppat.1002718. Epub 2012 May 17.
4
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.光滑念珠菌感染继发侵袭性念珠菌病长期治疗后卡泊芬净耐药性的产生。
Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5. doi: 10.1128/AAC.00473-08. Epub 2008 Aug 1.
5
Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.白念珠菌细胞壁几丁质升高赋予体内棘白菌素耐药性。
Antimicrob Agents Chemother. 2012 Jan;56(1):208-17. doi: 10.1128/AAC.00683-11. Epub 2011 Oct 10.
6
Candida lusitaniae MICs to the echinocandins are elevated but FKS-mediated resistance is rare.葡萄牙念珠菌对棘白菌素的最低抑菌浓度升高，但由FKS介导的耐药性罕见。
Diagn Microbiol Infect Dis. 2016 Jan;84(1):52-54. doi: 10.1016/j.diagmicrobio.2015.08.012. Epub 2015 Aug 28.
7
Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.临床显著的白色念珠菌中 micafungin 耐药性涉及葡聚糖合酶催化亚基 GSC1 (FKS1) 等位基因的修饰，随后是杂合性丢失。
J Antimicrob Chemother. 2010 May;65(5):842-52. doi: 10.1093/jac/dkq073. Epub 2010 Mar 16.
8
Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.在瑞典进行的为期一年的研究中，对收集到的念珠菌分离株进行棘白菌素药敏试验。
J Clin Microbiol. 2011 Jul;49(7):2516-21. doi: 10.1128/JCM.00201-11. Epub 2011 May 4.
9
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.了解新兴病原体耳念珠菌的棘白菌素类耐药性。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00238-18. Print 2018 Jun.
10
A Candida albicans strain with high MIC for caspofungin and no FKS1 mutations exhibits a high chitin content and mutations in two chitinase genes.一株对卡泊芬净 MIC 值较高且不存在 FKS1 突变的白念珠菌菌株表现出较高的几丁质含量和两个几丁质酶基因突变。
Med Mycol. 2011 Jul;49(5):467-74. doi: 10.3109/13693786.2010.538732. Epub 2010 Nov 26.
引用本文的文献
1
Unlocking the potential of Metschnikowia pulcherrima: a dive into the genomic and safety characterization of four plant-associated strains.挖掘美丽梅奇酵母的潜力：深入研究四株与植物相关菌株的基因组及安全性特征
Appl Microbiol Biotechnol. 2025 May 29;109(1):128. doi: 10.1007/s00253-025-13515-0.
2
Riverine mycobiome dynamics: From South African tributaries to laboratory bioreactors.河流真菌群落动态：从南非支流到实验室生物反应器
Mycology. 2024 Jan 30;15(4):631-650. doi: 10.1080/21501203.2023.2278309. eCollection 2024.
3
MetaFunc: taxonomic and functional analyses of high throughput sequencing for microbiomes.MetaFunc：微生物群落高通量测序的分类学和功能分析
Gut Microbiome (Camb). 2023 Jan 12;4:e4. doi: 10.1017/gmb.2022.12. eCollection 2023.
4
Mrs4 loss of function in fungi during adaptation to the cystic fibrosis lung.在适应囊性纤维化肺的过程中，真菌中的 Mrs4 功能丧失。
mBio. 2023 Aug 31;14(4):e0117123. doi: 10.1128/mbio.01171-23. Epub 2023 Jul 11.
5
Mrs4 loss of function in fungi during adaptation to the cystic fibrosis lung.真菌在适应囊性纤维化肺部过程中Mrs4功能丧失
bioRxiv. 2023 Apr 6:2023.04.05.535776. doi: 10.1101/2023.04.05.535776.
6
: Biology, Pathogenicity, Virulence Factors, Diagnosis, and Treatment.生物学、致病性、毒力因子、诊断与治疗
Infect Drug Resist. 2022 Aug 31;15:5121-5135. doi: 10.2147/IDR.S383785. eCollection 2022.
7
Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.2787 株酵母分离株的棘白菌素药敏模式：检测 FKS 突变的阈值的重要性。
Antimicrob Agents Chemother. 2022 May 17;66(5):e0172521. doi: 10.1128/aac.01725-21. Epub 2022 Apr 12.
8
A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints.一种在无欧洲抗菌药物敏感性试验委员会（EUCAST）临床断点情况下对酵母进行药敏分类的实用方法。
J Fungi (Basel). 2022 Jan 30;8(2):141. doi: 10.3390/jof8020141.
9
Participation of the ABC Transporter in Azole Resistance of .ABC转运蛋白在……的唑类耐药性中的作用
J Fungi (Basel). 2021 Sep 15;7(9):760. doi: 10.3390/jof7090760.
10
Balancing Positive and Negative Selection: Evolution of Candida lusitaniae .平衡正选择和负选择：葡萄牙假丝酵母的进化。
mBio. 2021 Mar 30;12(2):e03328-20. doi: 10.1128/mBio.03328-20.
本文引用的文献
1
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.重新审视棘白菌素类药物和念珠菌的临床折点：整合分子、临床和微生物学数据，以制定出基于物种的解释标准。
Drug Resist Updat. 2011 Jun;14(3):164-76. doi: 10.1016/j.drup.2011.01.004. Epub 2011 Feb 24.
2
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.近期接触卡泊芬净或氟康唑影响念珠菌血症的流行病学：一项涉及 2441 例患者的前瞻性多中心研究。
Antimicrob Agents Chemother. 2011 Feb;55(2):532-8. doi: 10.1128/AAC.01128-10. Epub 2010 Nov 15.
3
Novel FKS mutations associated with echinocandin resistance in Candida species.新型 FKS 突变与棘白菌素类耐药的念珠菌属相关。
Antimicrob Agents Chemother. 2010 May;54(5):2225-7. doi: 10.1128/AAC.00998-09. Epub 2010 Feb 9.
4
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?烟曲霉中的唑类抗性：环境中使用杀菌剂的副作用？
Lancet Infect Dis. 2009 Dec;9(12):789-95. doi: 10.1016/S1473-3099(09)70265-8.
5
Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.棘白菌素类药物和念珠菌属的野生型 MIC 分布和流行病学折点值
J Clin Microbiol. 2010 Jan;48(1):52-6. doi: 10.1128/JCM.01590-09. Epub 2009 Nov 18.
6
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.2019例念珠菌血症患者的流行病学及转归：来自前瞻性抗真菌治疗联盟登记处的数据
Clin Infect Dis. 2009 Jun 15;48(12):1695-703. doi: 10.1086/599039.
7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.FCY2和FCY1基因中的无义突变和错义突变是葡萄牙念珠菌临床分离株中氟胞嘧啶耐药性及氟胞嘧啶-氟康唑交叉耐药性的原因。
Antimicrob Agents Chemother. 2009 Jul;53(7):2982-90. doi: 10.1128/AAC.00880-08. Epub 2009 May 4.
8
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism.烟曲霉中唑类耐药性的出现及单一耐药机制的传播。
PLoS Med. 2008 Nov 11;5(11):e219. doi: 10.1371/journal.pmed.0050219.
9
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.白色念珠菌、热带念珠菌和克鲁斯念珠菌中fks1基因的突变，与采用欧洲抗生素敏感性试验委员会的方法在AM3培养基中发现的卡泊芬净最低抑菌浓度升高相关。
Antimicrob Agents Chemother. 2008 Sep;52(9):3092-8. doi: 10.1128/AAC.00088-08. Epub 2008 Jun 30.
10
Detection of caspofungin resistance in Candida spp. by Etest.采用Etest法检测念珠菌属中卡泊芬净的耐药性。
J Clin Microbiol. 2008 Jul;46(7):2389-92. doi: 10.1128/JCM.00053-08. Epub 2008 Apr 30.
Zotero 插件